Cure My Disease

Don't miss your cure!

 Log in / Sign up

French registry to track Real-World CAR-T outcomes in 5,000 patients

NCT ID NCT04328298

Knowledge-focused Sponsor: The Lymphoma Academic Research Organisation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is a registry that collects information on people with blood cancers who are eligible for CAR-T cell therapy. It will track up to 5,000 patients in France to see how long they live, how well the treatment works, and how long it takes to start therapy. The goal is to learn from real-world data to improve future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2019

Expected to finish

Dec 2038

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient eligible for a treatment with CAR-T for an hematological malignancy

Ages

0 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Retrospective inclusion : * Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or covered by French health insurance system (under post-ATU or MA) in a qualified center before activation of this register in this center * If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive Prospective inclusion : * Patient eligible for a treatment with CAR-T for an hematological malignancy which is covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a clinical trial with the same indication, after the activation of this register in this center. * Patient whose CAR-T indication has been validated during a multidisciplinary tumor board (RCP) of a qualified center, according to the ministerial order of 8 August 2019 * Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a qualified center according to the ministerial order of 8 August 2019 * If the patient is alive, the patient has been informed of the collection and use of their data, and the patient has not opposed this use. If the patient has died, the patient did not opposed the use of their data while alive. Exclusion Criteria Patient not registered with the social security in France

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematological malignancy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematopathology eligible or car-T cell treatment

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    36 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHP - Hôpital Cochin

    RECRUITING

    Paris, France

  • APHP - Hôpital Henri Mondor

    RECRUITING

    Créteil, France

  • APHP - Hôpital La Pitié Salpêtrière

    RECRUITING

    Paris, France

  • APHP - Hôpital Necker

    RECRUITING

    Paris, France

  • APHP - Hôpital Saint Antoine

    RECRUITING

    Paris, France

  • APHP - Hôpital Saint Louis

    RECRUITING

    Paris, France

  • APHP - Hôpital Universitaire Robert Debré

    RECRUITING

    Paris, France

  • CHRU Besançon - Hôpital Minjoz

    RECRUITING

    Besançon, France

  • CHRU de Lille - Hôpital Claude Hurriez

    RECRUITING

    Lille, France

  • CHU Angers

    RECRUITING

    Angers, France

  • CHU Brabois

    RECRUITING

    Vandœuvre-lès-Nancy, France

  • CHU Bretonneau

    RECRUITING

    Tours, France

  • CHU d'Amiens - Hôpital Sud

    RECRUITING

    Amiens, France

  • CHU d'Estaing

    RECRUITING

    Clermont-Ferrand, France

  • CHU de Brest - Hôpital du Morvan

    RECRUITING

    Brest, France

  • CHU de Dijon

    RECRUITING

    Dijon, France

  • CHU de Grenoble

    RECRUITING

    La Tronche, France

  • CHU de Montpellier

    RECRUITING

    Montpellier, France

  • CHU de Nantes - Hôtel Dieu

    RECRUITING

    Nantes, France

  • CHU de Nice

    RECRUITING

    Nice, France

  • CHU de Rennes - Hôpital Pontchaillou

    RECRUITING

    Rennes, France

  • CHU de Rouen Normandie

    RECRUITING

    Rouen, France

  • Centre Francois Magendie

    RECRUITING

    Pessac, France

  • Centre Henri Becquerel

    RECRUITING

    Rouen, France

  • Centre Hospitalier Lyon Sud

    RECRUITING

    Pierre-Bénite, France

  • Centre Léon Bérard

    RECRUITING

    Lyon, France

  • Gustave Roussy Cancer Campus

    RECRUITING

    Villejuif, France

  • Hôpital Dupuytren

    RECRUITING

    Limoges, France

  • Hôpital de la Milétrie - CHU de Poitiers

    RECRUITING

    Poitiers, France

  • Hôpital de la Timone

    RECRUITING

    Marseille, France

  • ICANS (Institut de Cancérologie Strasbourg Europe)

    RECRUITING

    Strasbourg, France

  • Institut Paoli Calmette

    RECRUITING

    Marseille, France

  • Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O)

    RECRUITING

    Toulouse, France

  • Institut d'Hématologie de Basse Normandie

    RECRUITING

    Caen, France

  • Institut d'Hématologie et d'Oncologie Pédiatrique (IHOP)

    RECRUITING

    Lyon, France

  • Institut de Cancérologie Hématologie Universitaire de Saint Etienne

    RECRUITING

    Saint-Priest-en-Jarez, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.